PDCD1 and cancer: Immune checkpoint inhibition (ICI) of the Programmed Cell Death Protein 1 (PD-1)/PD-Ligand 1 (PD-L1) axis has achieved considerable success in treating an ever-increasing variety of cancer types and is being increasingly applied both as a single modality and in combination therapies (15).